Basis of Presentation (Tables)

12 Months Ended

Apr. 30, 2025

Investments accounted for using equity method [abstract]

Summary of Subsidiaries which are Wholly Owned and Subject to Control

These consolidated financial statements include the financial statements of the Company and the following subsidiaries which are wholly owned and subject to control by the Company:


Name of Subsidiary		% Equity Interest - April 30, 2025, 2024 and 2023		Country of Incorporation		Functional Currency
ImmunoPrecise Antibodies (Canada) Ltd.		100%		Canada		Canadian dollar
ImmunoPrecise Antibodies (USA) Ltd. ("IPA USA")		100%		USA		US dollar
ImmunoPrecise Antibodies (N.D.) Ltd.		100%		USA		US dollar
ImmunoPrecise Antibodies (MA) LLC		100%		USA		US dollar
Talem Therapeutics LLC ("Talem")		100%		USA		US dollar
ImmunoPrecise Netherlands B.V.		100%		Netherlands		Euro
ImmunoPrecise Antibodies (Europe) B.V. ("IPA Europe")		100%		Netherlands		Euro
BioStrand B.V.		100%		Belgium		Euro
Idea Family B.V.		100%		Belgium		Euro
BioKey B.V.		100%		Belgium		Euro
BioClue B.V.		100%		Belgium		Euro

Summary of Effects of Adjustment on Comparative Periods in Financial Statements

The effects of this adjustment on the comparative periods in our Consolidated Statements of Financial Position and Comprehensive Loss as of April 30, 2025 are as follows:


	Previously reported			Adjustments			As adjusted
Balance sheet items: (in thousands)	4/30/2024			4/30/2024			4/30/2024
Deferred income tax liability		5,825			(1,757	)		4,068
Total liabilities		26,067			(1,757	)		24,310
Accumulated deficit		(100,265	)		1,705			(98,560	)
Accumulated other comprehensive income		2,025			52			2,077
Total shareholders' equity		33,921			1,757			35,678


	Previously reported (year)			Adjustments			As adjusted
Income statement items: (in thousands)	4/30/2024			4/30/2024			4/30/2024
Income taxes		1,526			1,062			2,588
Net loss for the period		(27,177	)		1,062			(26,115	)
Exchange difference on translating foreign operations		(600	)		(13	)		(613	)
Comprehensive loss for the period		(27,777	)		1,049			(26,728	)
Basic and diluted loss per share*		(1.06	)		0.04			(1.02	)

* Because of the net loss, basic and diluted loss per share are the same given potential dilutive common shares are excluded from the computation as their effect would be anti-dilutive.